- Home
- PIII vs ESLA Comparison
PIII vs ESLA Comparison
Compare PIII & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | ESLA |
|---|---|---|
| Founded | 2015 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.8M | 32.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PIII | ESLA |
|---|---|---|
| Price | $9.49 | $0.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $9.00 | $8.00 |
| AVG Volume (30 Days) | ★ 34.0K | 24.4K |
| Earning Date | 05-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,459,080,000.00 | N/A |
| Revenue This Year | $7.67 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.52 | $0.63 |
| 52 Week High | $16.89 | $3.15 |
Technical Indicators
Market Signals| Indicator | PIII | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.00 | 41.09 |
| Support Level | $9.00 | $0.70 |
| Resistance Level | $11.55 | $0.85 |
| Average True Range (ATR) | 0.58 | 0.06 |
| MACD | -0.13 | 0.00 |
| Stochastic Oscillator | 34.26 | 35.13 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all. It includes utilization management, care management, disease education, and maintenance of a quality improvement and quality management program for members assigned to the Company. The Company is also responsible for the credentialing of its providers, processing and payment of claims, and the establishment of a provider network for certain health plans.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.